FINNENCE ▪ THE WIRE FILE
THE WIRE · № 57256
Company■ Unclear/unknown
Phase 3 results posted: Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy — Teva Pharmaceuticals USA
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES2
ENTITIES1
STORY SIZE2 RECORDS
FIRST SEEN2026-09-30 12:00 UTC
LAST UPDATE2026-09-30 12:02 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Teva Phase 3 results for estradiol inserts are posted, but no efficacy or safety conclusions are given in the text.
Trial completion without outcome detail
CATALYST TO WATCH
Full results or regulatory action
MAIN RISK
Outcome direction unknown from text
FULL DISPATCH
Sponsor: Teva Pharmaceuticals USA; Status: Completed; Conditions: Dyspareunia; Interventions: Estradiol, Imvexxy, Placebo; Enrollment: 1050 (actual); First posted: 2022-11-16; Results posted: 2026-09-30; NCT: NCT05617820
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 2 TIMES · FIRST 2026-09-30 12:00 UTC · LAST 2026-09-30 12:02 UTC2026-09-30 12:00 UTCCompanyPhase 3 results posted: Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy — Teva Pharmaceuticals USACURRENT RECORD
2026-09-30 12:02 UTCNewsRobinhood unveils weekend hours, AI agents to allow users to trade nonstop
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases — Takeda2026-09-30 12:00 UTC
Phase 3 results posted: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases — Takeda2026-09-30 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis2026-09-30 12:03 UTC
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis2026-09-30 12:03 UTC
→CORRELATIONshares Healthcare
HealthPartners and Essentia Health Propose Major Merger2026-09-30 12:56 UTC
HealthPartners and Essentia Health Propose Major Merger2026-09-30 12:56 UTC
→CORRELATIONshares Healthcare
Masimo Wins Two OCTANE High Tech Awards - Company Recognized for 'Deal of the Year' and 'Best Technology Leadership Team'2026-09-30 13:05 UTC
Masimo Wins Two OCTANE High Tech Awards - Company Recognized for 'Deal of the Year' and 'Best Technology Leadership Team'2026-09-30 13:05 UTC
←CORRELATIONshares Healthcare
Union, governor’s office strike deal on state employee healthcare costs2026-09-29 22:54 UTC
Union, governor’s office strike deal on state employee healthcare costs2026-09-29 22:54 UTC
←CORRELATIONshares Healthcare
Astrocyte Pharmaceuticals Secures $9.5 Million Series B to Advance Phase 2 Clinical Development of Breakthrough TBI and Concussion Therapy AST-0042026-09-30 10:00 UTC
Astrocyte Pharmaceuticals Secures $9.5 Million Series B to Advance Phase 2 Clinical Development of Breakthrough TBI and Concussion Therapy AST-0042026-09-30 10:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.